Allos Therapeutics, Inc.
Allos Therapeutics Reports Fourth Quarter and Full Year 2009 Financial Results
Published in Medical Letter on the CDC and FDA, March 21st, 2010
On September 24, 2009, Allos obtained accelerated approval for FOLOTYN™ (pralatrexate injection) from the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This approval was based on overall response rate from our pivotal PROPEL trial. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated. FOLOTYN is the first and only drug approved by the FDA for this indication and represents a new treatment...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- JAMA and Archives Journals
Study examines outcomes associated with anemia management for patients with end-stage renal disease - Johns Hopkins University Bloomberg School of Public Health
Mosquitoes -- not birds -- may have carried West Nile virus across US - Wiley-Blackwell
Small wings travel far to spread West Nile virus - Chronic Obstructive Pulmonary Disease
Research from University of Connecticut in chronic obstructive pulmonary disease provides new insights - Fluorescein Therapy
Research on fluorescein therapy reported by M.B. Wallace et al - HIV/AIDS
Research from P.S. Belperio and co-authors provides new data about HIV/AIDS - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
